-+ 0.00%
-+ 0.00%
-+ 0.00%

ULTRAGENYX PHARMACEUTICAL EXEC SAYS U.S. PER PATIENT WHOLESALE ACQUISITION COST FOR FAYUVI IS SET AT $3.95 MILLION - CONF CALL

Reuters·09/17/2026 22:00:05